智通财经APP讯，神威药业(02877)发布2025年中期业绩，收益16.53亿元(人民币，下同)，同比减少20.8%;期内溢利6.15亿元，同比减少1.89%;每股基本盈利81分;拟派发中期股息每股11分。
公告称，于期内，集团毛利率有所下降，从去年同期的75.3%下调至72.2%。主要是由于产品原材料采购成本上升，加上集中采购影响药品价格所致。
随着整体销售额及毛利率于期内下跌，导致集团2025年首六个月经营利润亦比去年同期有所减少。但由于投资收入有所增加，而集团亦着力落实控费增效，销售及分销成本和行政开支与去年同期相比分别减少约20.7%及12.9%，令净利润较去年同期只轻微减少1.9%，而净利润率则从30.0%上调至37.2%。
集团继续以拓展口服制剂为重点发展策略。于2025年首六个月，口服产品占总销售额的比例达65.8%，而注射液产品则占总销售额34.2%。
注射液产品总销售额较去年同期下降27.4%，主要是由于清开灵注射液和参麦注射液销售额比去年同期分别减少50.1%及21.0%，而舒血宁注射液、冠心宁注射液、及丹参注射液等多个注射液产品的销售额亦分别减少6.3%、9.6%及24.6%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.